HK Stock Market Move | VIVA Biotech (01873) rose more than 13%, investment incubation company Arthrosi reached an acquisition agreement with Sobi.

VIVA BIOTECH (01873) rose by over 13%, as of the time of writing, up by 13.4% to 2.2 Hong Kong dollars, with a trading volume of 4.8154 million Hong Kong dollars. On the news front, on December 13, the global biopharmaceutical company Swedish Orphan Biovitrum AB ("Sobi") announced that it has reached an acquisition agreement with Arthrosi, a company in which VIVA BIOTECH participates in investment and incubation. According to the terms of the agreement, Sobi will pay a total consideration of up to $1.5 billion for this acquisition, including a $950 million upfront payment (subject to customary adjustments) and up to $550 million in regulatory and commercial milestone payments. The transaction is expected to be completed in the first half of 2026. As a result of this transaction, VIVA BIOTECH is expected to receive a maximum return of approximately $40 million, depending on the achievement of subsequent regulatory approvals and commercialization milestones. In addition, Arthrosi has also entered into a new Statement of Work (SOW) with VIVA BIOTECH's CDMO subsidiary, Lanhua Pharmaceuticals, for the supply of active pharmaceutical ingredients, and the company will continue to work with Arthrosi.